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Introduction
Sixty-ﬁve countries now offer the medications buprenorphine and methadone to treat opiate addic-
tion. Deemed “essential medicines” by the World Health Organization they are recognized by the 
United Nations Ofﬁce on Drugs and Crime, UNAIDS, and multiple national, regional, and inter-
national medical organizations to reduce drug injection and drug-related crime, and to improve 
public order, family satisfaction, return to employment, and adherence to HIV treatment.
Unfortunately, even when medication-assisted treatment programs with methadone or 
buprenorphine are available, they fail to reach many of those who could beneﬁt. One reason for 
this is the many requirements—including admission restrictions, limited hours of operation, 
waiting lists, and cumbersome prescription and storage requirements—that make it difﬁcult for 
patients to enter treatment.
This volume documents low-threshold methadone and buprenorphine programs—that is, 
programs that seek, in the spirit of harm reduction, to meet patients “where they’re at” and mini-
mize bureaucratic requirements.
Detoxiﬁcation vs. Maintenance
Methadone and buprenorphine are two of the best studied and most effective treatments for opi-
ate addiction. Both medicines can be used for detoxiﬁcation and maintenance purposes. Used 
for detoxiﬁcation, they reduce withdrawal symptoms and block the effects of subsequent opi-
ates. However, many individuals who are dependent on opiates return to illicit drugs after detox. 
Regular use of these medicines, sometimes referred to as maintenance treatment or therapy, can 
be used to reduce or eliminate cravings for heroin and other illicit opiates. During maintenance 
treatment, individuals are stabilized on methadone or buprenorphine for as long as is necessary 
to help them avoid harmful drug use. The beneﬁts of maintenance treatment, and the absence of 
negative side effects, are well documented in scientiﬁc literature. 
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Low-threshold Programs
Low-threshold programs are ﬂexible in their organization of services and eligibility requirements. 
The objective is treatment accessibility for the greatest number of individuals in need. Interventions 
are designed speciﬁcally to engage and retain some of the most marginalized and hardest to reach 
populations. The non-judgmental approach of low-threshold programs aims to reduce negative 
health outcomes while not requiring individuals to completely abstain from illicit drug use. 
Innovative Programs 
From Canada to Croatia, countries throughout the world offer innovative models for methadone 
and buprenorphine provision. Accessibility is the cornerstone of methadone treatment in Hong 
Kong, where individuals can start treatment on demand, usually receiving their ﬁrst dose the day 
they sign up at the clinic. In France, patients receive their methadone or buprenorphine through 
a prescription, as they would any other medication, which has the effect of destigmatizing medica-
tion-assisted treatment and mainstreaming the practice. 
Early and comprehensive implementation of harm reduction services in Slovenia is cred-
ited with keeping HIV prevalence among injecting drug users below one percent. Slovenia also 
offers slow-release morphine as a third treatment option to those dependent on opiates. Croatia’s 
progressive model of medication provision, linked with comprehensive services and referrals, was 
established to be widespread and uncontroversial. In the Netherlands, the use of a bus to distribute 
methadone is part of the “methadone dispensing circuit” intended to reach a broad number of 
at-risk clients and to give clients incentives to progress through low, medium, and high-threshold 
medication provision. Vancouver, Canada’s model includes pharmacy dispensing and compre-
hensive “woman-centered, harm reduction-based” health and social support services for pregnant 
opiate users, including methadone provision. 
Each of these programs offers new insights for how countries can make methadone and 
buprenorphine treatment accessable and oriented to meet the needs of people dependent on opi-
ates, and in doing so, achieve progress in HIV and overdose prevention.  
L O W E R I N G  T H E  T H R E S H O L D    7
Methadone on Demand: 
The Hong Kong Model
Though thousands of Hong Kong residents are dependent on opiates, levels of HIV among inject-
ing drug users are far lower than those found in neighboring countries or other parts of China. 
Overall rates of HIV among injecting drug users in Hong Kong are less than one percent.1 The 
widespread availability of methadone is thought to be the major reason why.2
Hong Kong authorities have demonstrated commitment to methadone since before the 
AIDS epidemic, opening the ﬁrst methadone clinic in 1972 and continuing to support low-thresh-
old methadone detoxiﬁcation and longer-term methadone maintenance treatment ever since.3 The 
region has 20 operational methadone clinics4 and is one of the only places in Asia where metha-
done maintenance treatment is easily available upon demand. More than 70 percent of heroin 
users attend methadone clinics at any one time.5 The vast majority of clients (about 98 percent) 
opt for the clinics’ methadone maintenance programs, rather than the detoxiﬁcation programs.6
A harm reduction media campaign in 2000 promoted medication-assisted treatment for 
reducing personal and societal harm associated with drug injection. This was the ﬁrst time that the 
social marketing of methadone treatment was introduced as a government effort, with community 
support. In 2002, the Department of Health launched a publicity campaign with the slogan “Break 
the needle habit. Methadone does it.” The government described the campaign as an effort to 
increase acceptance of methadone treatment among drug users and the wider public.
From the Department of Health, Government of Hong Kong Special Administrative Region website: 
http://www.info.gov.hk/aids/harmreduction/english/3_3.htm
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Accessibility is the key to Hong Kong’s methadone treatment approach. In contrast to the 
United States and Western Europe, where entrance into methadone treatment frequently requires 
protracted paperwork, waiting lists, and referrals, treatment in Hong Kong is generally available 
on demand, the same day it is requested. Opiate-dependent people who are under the age of 18 
are allowed into the program, but are generally requested to provide evidence of parental consent.7 
The fee for treatment has remained unchanged for years at HK$1 (less than US$0.80) per day. 
Clinics operate seven days a week and are open early and late to serve the estimated 57 percent of 
participants who are employed.8 
In contrast to many other countries where methadone program staff are subject to rigid 
educational demands and certiﬁcation requirements, Hong Kong clinics have historically been 
supervised by a physician but staffed by Auxiliary Medical Service volunteers whose regular occu-
pations may range from shoe salesman to housewife to bank clerk. Working for a nominal fee, 
these volunteers have enabled clinics to operate at extended hours with minimal expenses.9 
Patients, too, are less strictly monitored: while urine tests are collected to assess general 
program effectiveness in limiting heroin use, these reportedly aren’t used to disqualify patients 
from participation. Since 2004, visitors to the clinic have undergone regular urine screenings for 
HIV (clients preferred urine screenings over blood screenings). These screenings serve to promote 
early HIV detection, provide information to clients about the connections between HIV and drug 
use, and link HIV detection and treatment services.10
Besides offering methadone, the clinics also provide social workers, group counseling, and 
tetanus vaccinations. The majority of clinics share facilities with general outpatient clinics. All 
clinics display HIV prevention materials and make condoms freely available.11 
The Hong Kong government has reafﬁrmed its commitment to ongoing, accessible metha-
done treatment. Health ofﬁcials are engaged in efforts to strengthen counseling and HIV reduc-
tion measures for people who attend the clinics.12
Notes
1. Shui-shan, L. 2005. The contribution of methadone maintenance treatment to HIV prevention—the case of Hong 
Kong. www.nd.gov.hk/conference_proceedings/Drugs_proBK_Part3/Drugs_proBK_LeeSS.pdf. Accessed 
May 15, 2008.
2. See: Hong Kong Advisory Council on AIDS. Recommended HIV strategies for Hong Kong 2007–2011. 
www.hivpolicy.org/Library/HPP001244.pdf. Accessed May 15, 2008; and Shui-shan, 2005. 
3. See: Action Committee Against Narcotics. 2000. Report on review of methadone treatment programme. 
Government of Hong Kong.
4. See: Reid, G. and G. Costigan. 2002. Revisiting ‘the hidden epidemic’: A situation assessment of drug use in 
Asia in the context of HIV/AIDS. Fairﬁeld, Australia, The Centre for Harm Reduction at The Burnet Institute; 
and, Department of Health, Government of Hong Kong Special Administrative Region. N.D. Harm reduction 
website. 2009. www.info.gov.hk/aids/harmreduction/english/3_3.htm Accessed April 23, 2009.
5. Special Preventive Programme Centre for Health Protection, Department of Health, Hong Kong Special 
Administrative Region. 2007. HIV Surveillance Report—2006 Update. www.hivpolicy.org/Library/HPP001440.
pdf. Accessed May 15, 2008.
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6. Working Group on HIV Prevention among Injecting Drug Users in Hong Kong. 2006. Report of community 
assessment and evaluation of HIV prevention among injecting drug users in Hong Kong 2006. Hong Kong 
Advisory Council on AIDS. www.info.gov.hk/aids/pdf/g172.pdf. Accessed May 15, 2008.
7. Narcotics Divison, Security Bureau. 2000. Report on review of methadone treatment programme. www.nd.gov.
hk/MTP_e.htm. Accessed May 15, 2008.
8. For more details on clinics and treatment services, see: Society for Aid and Rehabilitation of Drug Abusers. 
2007. Treatment and rehabilitation services: Methadone clinic counseling service. www.sarda.org.hk/eng/sarda_
home.html. Accessed May 15, 2008; and, Pi, P. 2005. Counseling services in methadone clinics – A Hong Kong 
model. www.nd.gov.hk/conference_proceedings/Drugs_proBK_Part4/Drugs_proBK_PeterPi.pdf. Accessed 
May 15, 2008. 
9. See: Newman, R.G. 1985. Narcotic addiction and methadone treatment in Hong Kong: Lessons for the 
United States. Journal of Public Health Policy 6 (4): 526-538; and, Shui-san, 2005.
10. Shui-san, 2005.
11. Working Group, 2006. 
12. Action Committee Against Narcotics, 2000; HIV Surveillance Report, 2007.
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Treatment by Prescription 
in France
France began offering buprenorphine treatment by prescription in 1996. Today an estimated 
90,000 patients receive buprenorphine, and an additional 10,000 are on methadone treatment.1 
Medication-assisted treatment reaches an estimated 70 percent of drug users in France, and has 
resulted in an 80 percent reduction in heroin overdose deaths, a 75 percent reduction in HIV 
prevalence among drug users, and a 75 percent reduction in drug-related crime.2 Treatment with 
methadone or buprenorphine is credited with saving 3,500 lives since 2004.3 
France began a comprehensive harm reduction program in 1995, in response to a growing 
AIDS epidemic.4 The program included drug user outreach and education, needle and syringe 
exchange programs, and the expansion of medication-assisted treatment.5 
Number of Arrests for Heroin Use, France: 1990–2005
Graph courtesy of Dr. M.P. Carrieri.
16.000
14.000
12.000
10.000
8.000
6.000
4.000
2.000
0
1990 1995 2000 2005
6,522
8,544
11,753 12,016
13,457
13,229
10,445
9,124
6,019
4,911 4,831
3,796
3,448 3,258
3,730
4,485
Methadone and Buprenorphine
Introduced: 1995–1996
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Methadone, which was introduced in France in 1995,6 is initiated only in drug maintenance 
clinics, though the prescription may be transferred to a general practitioner after the patient is 
stabilized.7 There is no registration of users, no biological testing for use of other substances, and 
patients are not required to undergo any type of counseling. 
Methadone is generally prescribed for a maximum of 14 days with divided doses available 
every seven days at the dispensing pharmacy. Prescribing physicians may allow longer periods for 
the divided dose. Buprenorphine (prescribed in its pure form as Subutex) can be prescribed by any 
general practitioner, without special training or licensing. Clinics also have general practitioners 
who can prescribe Subutex.
Similar to methadone but with a longer maximum prescription length of 28 days, Subutex is 
typically prescribed with divided doses every seven days unless otherwise ordered by the prescrib-
ing physician. Dispensing pharmacists are expected to provide buprenorphine daily for the ﬁrst 
several days and directly observe dose-taking before beginning unsupervised administration.
Though all general practitioners can prescribe buprenorphine, in practice, 26 percent of 
doctors prescribe to 75 percent of users undergoing treatment.8 Unlike in the United States, where 
physicians face a 30-patient cap, in France there is no limit to the number of patients that one 
physician may treat with buprenorphine. 
Methadone is free in clinics, while buprenorphine is purchased at a pharmacy and reim-
bursed through classic prescription coverage, with third parties often paying for most or all of the 
treatment.9 
Access to Methadone and Buprenorphine and Decline in the Number of Overdose Deaths 
France: 1990–2003
Graph courtesy of Dr. M.P. Carrieri.
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The prescription-based model is credited with mainstreaming drug dependence treatment 
into primary care, and therefore destigmatizing it.10 It has also resulted in more comprehensive 
treatment for patients—many French physicians now prescribe both methadone or buprenorphine 
treatment and antiretroviral treatment to HIV-positive patients,11 resulting in a better ability to 
manage drug interactions. 
PATIENTS’ VOICES
“So many of my friends overdosed, so many died. I do not know how I escaped. How 
come you came so late? Thanks to opiate substitution treatment, I am safe now.”
—Bruno
“Coming to the clinic is a pleasure, everybody is friendly, aware of our realities and non 
judgmental. Usually drug users are loathed and rejected. I was given Subutex on my 
very ﬁrst visit, and I could quickly move forward.”
—Laurent
“To my family, I was a junkie. My mother is old and lives in Algeria. Now with Subutex, 
I can have a 4-week prescription, take a month’s leave and go and visit her, like my 
brothers and sisters.”
—Brahim
“The ﬁrst time I came, it was closing time and I was in withdrawal. The doctor had a 
short interview with me, and prescribed one Subutex until the next day. I did not come 
back as I was told, but the next time I was in trouble I came again. Again I was well met 
and helped, so I came back for good and started real treatment.”
—Christophe
“My boyfriend and I were on heroin. We were both given Subutex as soon as we came 
here. Stephane was working and very soon went to a general practitioner. I stayed in 
the clinic longer, because we decided to have a baby. Lea is nine years old now. The 
staff was at the maternity hospital when she was born, both to congratulate me, and 
see that we were provided the adequate care. I am proud to say that mine was the ﬁrst 
Subutex-baby of the clinic.”
—Sophie
Notes
1. Carrieri, M.P., L. Amass, et al. 2006. Buprenorphine use: The international experience. Clinical Infectious 
Diseases, 43: S197–215.
2. Carrieri, M.P. and B. Stambul. 2007. Treatment shortage fuels drug diversion. [Letter to the editor]. The 
Baltimore Sun: December 29. 
3. Carrieri, M.P. and B. Spire. 2008. Harm reduction and control of HIV of injecting drug users in France. The 
Lancet, 376: 448. 
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4. Roux P., V. Villes et al. 2008. Buprenorphine in primary care: Risk factors for treatment injecting and 
implications for clinical management. Drug and Alcohol Dependence, 97(1-2): 105–113.
5. Carrieri, M.P. and B. Stambul. 2007.
6. Roux P., V. Villes et al. 2008.
7. Guichard A., F. Lert et al. 2007. Buprenorphine substitution treatment in France: drug users’ views of the 
doctor-user relationship. Social Science and Medicine, 64(12): 2578–2593. 
8. Carrieri, M.P., L. Amass, et al. 2006.
9. Guichard A., F. Lert et al. 2007.
10. Carrieri, M.P., L. Amass, et al. 2006.
11. Ibid.
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Slovenia: High Coverage, 
Low HIV Prevalence
Slovenia and Croatia  have offered methadone and buprenorphine treatment longer than any other 
country in Eastern Europe; the two countries also have the lowest prevalence rates of HIV among 
injecting drug users in that region.1 Early and comprehensive implementation of harm reduction 
services is credited with keeping Slovenia’s HIV prevalence rate among drug users below one 
percent.2 This comprehensive package includes widely available and easily accessible methadone 
and buprenorphine treatment, as well as treatment with slow-release morphine. Additionally, 
treatment is available in prisons. 
High Coverage
Since 1994, Slovenia has offered medication-assisted treatment at no charge to clients through 
a network that now comprises 19 specialized Centers for Prevention and Treatment of Drug 
Addiction, including 18 local outpatient centers and one national center, which coordinates the 
network and offers both inpatient and outpatient services.3 In some rural areas where residents 
live far away from treatment centers, general practitioners and pharmacists dispense treatment 
to opioid-dependent persons.
In late 2006, 2,689 people received medication-assisted treatment and 1,730 additional 
patients attended the centers to receive some other forms of treatment and care.4 Estimates sug-
gest that slightly less than half of the “problem drug users”5 were registered at centers throughout 
Slovenia and approximately one-third received medication-assisted treatment at those centers.6 
Within the European Union, these ﬁgures represent a high national coverage.7
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Methadone is prescribed to 81 percent of patients receiving treatment, generally in liq-
uid form, while buprenorphine tablets are taken by 13 percent of the opioid-dependent clients.8 
Subsitol, slow-release morphine tablets, became available in 20059 and were prescribed to six 
percent of clients the next year.10
National Coverage: Nineteen Treatment Centers in Slovenia
Map Courtesy of Dr. Andrej Kastelic, as cited in Simon and Iliuta, 2006.
Estimated Opiate Dependent Drug Users in Medication-Assisted Treatment 
per 100,000 Population
Courtesy of Dr. Andrej Kastelic. Data source: European Monitoring Centre for Drugs and Drug Addiction.
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Flexible Eligibility Requirements
Medical doctors are responsible for new patient intake, prescription, dosage, and pick-up sched-
ules, but nurses generally dispense medication in the centers. The centers maintain ﬂexible poli-
cies regarding take-home doses, but patients are typically given no more than one week’s worth 
of medication at a time. There are no waiting lists, but clients must have valid health insurance, 
which is free for every citizen and completely covers the cost of the medications.11 Patients must 
have a general practitioner to enroll and be at least 16 to receive methadone and 15 for prescrip-
tions of buprenorphine or slow-release morphine.
There is no national register of drug users; treatment centers report only coded individ-
ual data to the National Institute of Public Health, and client information is not reported to the 
National Health Insurance Institute.12
In addition to the national network of medication-assisted treatment centers ﬁnanced 
by the Health Insurance Institute of Slovenia, the Ministry of Health, and the Ministry of 
Labor, Family and Social Affairs fund both high- and low-threshold NGO-run drug treat-
ment services. These services include a range of prevention and intervention services 
from needle and syringe exchange to therapeutic communities and self-help groups. 
Medication-assisted Treatment in Prisons
Prisons in Slovenia have offered medication-assisted treatment since 2003; in 2007, 586 inmates 
received treatment in seven Slovene prisons.13 That number represents 53 percent of the estimated 
1,090 drug users in custodial settings in Slovenia in 2007. Slovenia has become a model in the 
region for ensuring the highest attainable level of care for drug dependent inmates: In 2007, 
Serbian prisons opened their ﬁrst “drug-free units,” which offer treatment and support services, 
including medication-assisted treatment, and are based on the Slovenian program.14 
Percentage of Patients in Custodial Settings Recieving Treatment
Data courtesy of Dr. Andrej Kastelic.
1.800
1.300
800
300
2003 20062004 2005 2007
 Number Recieving Medication-assisted Treatment      Number of Drug Users
1 8    S L O V E N I A :  H I G H  C O V E R A G E ,  L O W  H I V  P R E V A L E N C E
Notes
1. Carrieri, M.P., L. Amass. 2006. Buprenorphine use: the international experience. Clinical Infectious Diseases, 
43: S197–215.
2. Simon, A.W. and C. Iliuta. 2006. NGO Perspectives on HIV/AIDS in Slovenia. http://ec.europa.eu/health/
ph_projects/2004/action3/docs/2004_3_11_frep_a6_en.pdf. Accessed April 23, 2009.
3. Trautmann, F., N. Rode et al. 2007. Evaluation of substitution maintenance treatment in Slovenia. Assessing its 
quality and efﬁciency. Trimbos Institute and the Faculty of Social Work at the University of Ljubljana. Also, 
see Kastelic, A. and T. Kostnapfel Rihtar. 2005. Ten years of organized drug addiction treatment in the 
Republic of Slovenia. Zdrav Var, 44: 111–112.  
4. Kastelic, cited in Trautmann, Rode et al. 2007.
5. Problem drug use deﬁned as “those with intravenous drug use (IDU) or long duration/regular use of 
opiates, cocaine or amphetamines, during a one-year period, in the age group of 15–64.” (National Report, 
2004, Grgic-Vitek, 2004, cited in Trautmann et al. 2007).
6. Trautmann, Rode et al. 2007.
7. Van der Gouwe et al. 2006, cited in Trautmann, Rode et al. 2007.
8. Trautmann, Rode et al. 2007.
9. European Monitoring Centre for Drugs and Drug Addiction. 2008. Drug Situation: Country Overviews: 
Slovenia. http://www.emcdda.europa.eu/html.cfm/index35999EN.html. Accessed November 14, 2008.
10. Kastelic, cited in Trautmann, Rode et al. 2007.
11. Trautmann, Rode et al. 2007.
12. European Monitoring Centre for Drugs and Drug Addiction. 2008.
13. Kastelic, A. 2008. E-mail correspondence, November 2008.
14. Organization for Security and Cooperation in Europe. 2007. OSCE establishes ﬁrst drug-free units in 
Serbia’s prisons. www.osce.org/serbia/item_2_25725.html. Accessed April 23, 2009.
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Widespread and Uncontroversial: 
Methadone and Buprenorphine 
in Croatia
Today Croatia and Slovenia, both of which have had methadone programs since the mid 1990s, 
account for 52 percent of patients receiving medication-assisted treatment for opioid dependence 
in Central and Eastern Europe.1 A belief among Croatia’s medical professionals that addiction 
should be treated as any other disease, and methadone and buprenorphine prescribed as any other 
medicine, has enabled the country to embrace one of the most progressive models of methadone 
and buprenorphine provision in the region.2 
Outpatient methadone and buprenorphine treatment is available at 21 clinics, and through a 
dense network of general practitioners. Provision of medication-assisted treatment has been suc-
cessful in Croatia, in part because it was introduced without strict regulation or widespread public 
debate.3 In 2004, Croatia approved buprenorphine for treatment of opioid dependence.
In 2006, the World Health Organization reported an estimated 10,000 injecting drug users 
out of a total population of 4,556,000 and today the number of injecting drug users is estimated 
to be between 15,000 and 18,000.4 Despite such a large population of injectors, the low-threshold 
accessibility and availability of medication-assisted treatment and other harm reduction services, 
including needle and syringe programs, has helped keep Croatia’s HIV prevalence among injectors 
at a low one percent since 1991.5 That proportion has not increased over the last 15 years.6
The most recent data reports that there are currently 5,703 opiate users in Croatia receiv-
ing medication-assisted treatment, with 2,141 on methadone and 1,164 receiving buprenorphine.7 
Dr. Ante Ivancic, of the Center for Addiction Treatment in Porec, Croatia, believes the 2007 data 
underreports today’s numbers by about 20 percent: He estimates the number of patients on 
methadone to be 3,500 and the number of patients on buprenorphine to be 2,500.8 Over half of 
the country’s 2,400 general practitioners have patients on maintenance treatment and all general 
practitioners are obligated to provide treatment should their patients require it.9
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Flexible Take-home Doses
Outpatient treatment centers are responsible for initial assessment, prescribing a starting dosage 
and dose adjustments, psychosocial counseling, urine screens, and epidemiological data collection. 
General practitioners cooperate with specialists at the centers for outpatient treatment and pre-
scribe the methadone or buprenorphine, supervise consumption, and provide take-home doses. 
Daily methadone doses are adjusted to the patient’s needs, and may range anywhere from 
10 mg to more than 100 mg.10 Methadone is provided at the general practitioner’s ofﬁce and take-
home doses are common and available for up to one week for a large percentage of patients. 
Nurse Prepares Methadone Take-home Dose by Crushing Methadone Tablets 
and Mixing with Orange Powder
Photo courtesy of Dr. Ante Ivancic.
Buprenorphine is prescribed as a take-home medication for one week at a time and patients 
can get it in the pharmacy just like any other medicine. Supervised consumption of buprenorphine 
is extremely rare. There is no ofﬁcial data on the average dose of buprenorphine but if the dose is 
low, between 2–6 mg, patients may have their take-home prescription extended beyond one week. 
The average dose is estimated to be increasing and likely falls somewhere around 6 mg.11
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Comprehensive Services and Referrals
The outpatient treatment centers, located in areas with a high prevalence of injecting drug use, 
are staffed with multidisciplinary teams, including medical practitioners, psychologists, social 
workers, and nurses; they provide psychosocial counseling, perform evaluations, and collect epi-
demiological data. There are no waiting lists to enter the program, and all services are paid for by 
the National Health Institute. Individual client data from both inpatient and outpatient clinics are 
recorded in a Register of Persons Treated for Psychoactive Drugs Misuse.
Outpatient treatment centers communicate and coordinate with other institutions, referring 
patients with HIV or hepatitis C to infectious disease specialists, and pregnant patients to obstetric 
care. Centers also maintain good relationships with law enforcement ofﬁcials. Persons charged 
with opiate possession are offered the option of initiating treatment at the outpatient treatment 
centers; if the person accepts such treatment, criminal proceedings are dropped.12
There is no obligation to attend any service on a regular basis and the terms for treatment 
in the specialized outpatient centers are individualized depending on the status and needs of 
the client. While urine screens are used, patients are not banned from the program if drugs are 
detected, and retention rates are high at about 85 percent.13
Notes
1. Carrieri, M.P., L. Amass. 2006. Buprenorphine use: the international experience. Clinical Infectious Diseases, 
43: S197–215.
2. Ivancic, A. 2003. Methadone therapy in Croatia. Annales de Medecini Interne,154: 51–54. See, also, Sarang 
A., R. Stuikyte, et al. 2007. Implementation of harm reduction in Central and Eastern Europe and Central 
Asia. International Journal of Drug Policy, 18: 129–35. 
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Methadone by Bus in Amsterdam
Methadone reaches an estimated 2,700 (or 68 to 77 percent) of the 3,500 to 4,000 opiate users in 
Amsterdam.1 The municipality has achieved this wide coverage through a program of integrated 
low-, medium-, and high-threshold methadone provision. A study of drug users in Amsterdam 
found that full participation in harm reduction programs2 was associated with a two- to threefold 
reduction in the risk of HIV seroconversion, and a six- to sevenfold reduction in the risk of hepa-
titis C seroconversion. One component of Amsterdam’s harm reduction program is a bus that 
distributes methadone to about 200 people throughout the city—without a waiting list. 
Heroin was introduced to the Netherlands in 1972, and in 1979, the municipality of 
Amsterdam initiated the program of integrated low-, medium-, and high-threshold methadone 
provision, known as the Methadone Dispensing Circuit. The idea of the system is to reach the 
broadest number of, and most at-risk, clients through low-threshold programs, while giving cli-
ents incentives to move to higher-threshold programs.3 Drug users can freely move between the 
different programs. 
High-threshold programs consist of addiction clinics where drug use is not tolerated.4 
Medium-threshold programs consist of general practitioners and psychiatrists who prescribe 
methadone to patients in one- or two-week take-home doses; patients may ﬁnd this approach 
less stigmatizing, as methadone is dispensed similarly to other medications.5 Any physician can 
prescribe methadone; a special license is not needed.
Mobile Methadone 
About half of those receiving methadone through the dispensing circuit do so through low-thresh-
old programs.6 Low-threshold methadone provision is delivered by mental health centers and an 
innovative mobile bus. The mobile program began in 1979 as a response to concerns that a ﬁxed 
location methadone dispensary would draw drug users to an area7 and in an effort to reach as many 
drug users as possible.8 The ﬁrst mobile clinic was run out of a refurbished but makeshift city 
bus; today the methadone bus is outﬁtted with a heating system, automatic doors, video-screens, 
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hygienic means for needle and syringe disposal, telephones, and security windows. The bus runs 
365 days a year, making four one-hour stops each day.
Road Sign in Amsterdam Alerts Drivers to Parking Ban Between Designated Hours 
When Methadone Bus Is Stationed There
Photo courtesy of Gerrit Van Santen.
Before receiving methadone from the bus, clients must be assessed at health centers; dos-
ages are set by doctors at these clinics, as the buses are staffed only by nurses and a driver. To 
prevent double prescription, all programs participate in a central methadone registry. The registry 
records dosage, type, and site of all methadone prescriptions, along with date of ﬁrst contact, 
gender, date of birth, and nationality. The bus dispenses methadone free of charge—it is ﬁnanced 
by the health insurance system (every Dutch citizen is required to have health insurance; those 
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who can’t afford it are insured through social security). The system aims to keep in touch with 
drug users most at risk, including sex workers, pregnant women, and people living with HIV.9 
Methadone is dispensed in liquid form daily and patients may progress from daily dosing to weekly 
visits with take-home tablets in between. 
Patient-centered
Though patients are required to have regular contact with a medical doctor and be entered into 
the methadone registry, there is no mandatory contact with a counselor and continued drug use 
while receiving methadone is not grounds for exclusion. The methadone registry is controlled 
under the Dutch health care information protection law, and information can only be shared with 
the permission of the patient. 
The bus dispenses not only methadone, but also provides free condoms, clean needles and 
syringes, and other prescribed medications. Each patient is tested annually for HIV, hepatitis C 
virus, syphilis, and tuberculosis, and hepatitis B vaccinations are given. Case managers are avail-
able to help devise treatment plans, and testing is accompanied by counseling and education.
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Vancouver: Integrated 
Low-threshold Models of Care
In 1997 public health ofﬁcials in Vancouver, Canada declared a state of emergency in response to 
a severe injection-driven HIV epidemic that made evident the ineffectiveness and inaccessibility 
of current treatment provision.1 As a consequence of the city’s HIV epidemic, there was a move to 
expand methadone maintenance programs and institute broader harm reduction measures. The 
city encouraged doctors to become licensed to prescribe methadone and pushed for community 
pharmacies to become licensed dispensaries. 
In 1995, the number of patients on methadone maintenance treatment in the province of 
British Columbia, Canada, numbered 1,0002 and by 2007 that number had grown to 8,985.3 
Since a peak of 416 overdose deaths in 1998, methadone treatment has contributed to a 62 
percent reduction in such deaths among injection drug users.4 Medication-assisted treatment is 
also credited with a 57 percent reduction, since 1996, in the annual rate of new HIV infections 
among injection drug users.5
 
Prescribing Physician Discretion
Methadone is prescribed by licensed physicians and dispensed by licensed pharmacies. 
Prescriptions are generally issued on a weekly basis but this is at the discretion of the treating 
physician.6 The starting dose for most patients begins at 40 mls and increases every few days or 
at the prescribing physician’s discretion.7 Prescriptions are ﬁlled at community-based participating 
pharmacies; patients typically go to the same pharmacy every day for witnessed ingestion until 
they qualify for take-home doses.8
Though patients are required to have regular contact with their prescribing physician and to 
be registered in the provincial methadone maintenance program, selection of patients for metha-
done treatment, dose prescription, and patient monitoring is the sole responsibility of the treating 
physician. While the College of Physicians and Surgeons of British Columbia recommends urine 
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drug screens when patients have take-home doses, the decision to screen and frequency of screen-
ing are left up to the treating physician. Patients are not excluded from the program for continued 
drug use while on methadone. 
There is no age requirement and while doctors are required to assess patients before pre-
scribing methadone, subsequently they typically see patients only twice monthly.9 Patients gener-
ally see the same doctor and use a consistent pharmacy while receiving treatment but transfers to 
another methadone prescribing physician are possible, if requested by either the patient or doctor. 
Of the 321 physicians in British Columbia who are authorized to prescribe methadone for opiate 
dependence, 199 of them have registered patients.10 
Buprenorphine was approved for use in Canada in 2005 both in its pure form, Subutex, 
and in the combination tablet, Suboxone. Only Suboxone is commercially available. Suboxone 
combines buprenorphine and naloxone—a drug used to reverse opiate overdose—in a 4:1 ratio. 
This combination was developed to discourage misuse, diversion, and injection, and to increase 
patient access to treatment. In Canada the Suboxone tablet is not yet covered by the provincial drug 
beneﬁts plan and there are only a small number of patients with prescriptions.11 
Pharmacy Dispensing
In 2008, there were approximately 76 pharmacies dispensing the drug and 13 of those were 
located in the Downtown Eastside neighborhood.12 The Downtown Eastside is one of the oldest 
neighborhoods in the city and the most notoriously low-income and under-served. The Downtown 
Eastside has an estimated 18,000 residents. In 2007 the UN Population Fund reported that hepa-
titis C rates in the Downtown Eastside were nearly 70 percent, while the neighborhood’s HIV 
prevalence rate of 30 percent rivaled Botswana’s.13 Of the 8,985 patients registered in methadone 
programs in British Columbia14 approximately 2,849 of those patients reside in Vancouver and 
1,323 of those are living in the Downtown Eastside neighborhood.15 
There are waiting lists to enroll in methadone maintenance in Vancouver16 and experts 
believe that treatment may still be reaching only half of the population in need, largely because 
of barriers to access and the incapacity of those with dual diagnoses, or living with HIV or 
hepatitis C.17 
The Downtown Eastside is home to three innovative models of low-threshold care that work 
to reduce those barriers and support those hardest to reach.
Sheway
Sheway, meaning “growth” in Coast Salish, a First Nations language, is a program that responds 
to the urgent needs of pregnant and newly parenting women who struggle with substance use 
issues. A 1993 study of babies born to mothers in the Downtown Eastside showed that 40 percent 
had Fetal Alcohol Syndrome/Neonatal Abstinence Syndrome, 33 percent had low birth weights, 
and nearly 100 percent were removed by the Ministry for Children and Family Development.18 
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In response, concerned community members forged an initiative to offer these women compre-
hensive, “woman-centered, harm reduction based” health and social support services.19
“It’s a safe place; instead of being out there…
I’m lucky this place is here, otherwise I’d probably 
be six feet under long ago.”
—Sheway participant (Payne, 2007)
Before Sheway was established, most programs in the city approached women who were 
pregnant and using drugs with judgment and suspicion; pregnant women were refused services 
or required to be abstinent from drugs during treatment and then separated from their babies at 
birth.20 The result of this approach was that many women simply avoided prenatal care to avoid 
hostility or out of fear of losing their children, putting both mother and child at increased medical 
risk, and almost guaranteeing separation at delivery. 
Sheway’s comprehensive health and social services include street outreach, drop-in services, 
and prenatal care and support to pregnant women and women with children up to 18 months of 
age. The program has drop-in hours Monday through Friday, including a daily free hot lunch. An 
extensive, multidisciplinary staff provides assistance with food and nutrition, advocacy for safe 
affordable housing, referrals and access to medical care, methadone maintenance, immuniza-
tions, contraception counseling, testing and counseling for HIV and other sexually transmitted 
infections, and resources for newborns.
With British Columbia Women’s Hospital as its acute-care provider for withdrawal man-
agement, Sheway connects women with other programs to provide methadone maintenance 
at discharge from Sheway. Sheway does not use urine screening in patient monitoring, believing 
it often deters trust and relationship-building, however if a woman requests a urine screen to 
show government ofﬁcials that she is not using illicit drugs, staff will provide her with the 
requested screen.
Research and evaluation are an ongoing component of the program; one report documented 
improvement in the program’s success at keeping mothers and children together after deliv-
ery: among Sheway clients the child removal rate fell from 30 percent in 2002 to 21.3 percent 
in 2005.21 
Fir Square
Prior to 2003, Sheway was the only program speciﬁcally offering perinatal services to substance-
using women in Vancouver.22 In 2003, the British Columbia Women’s Hospital expanded on-site 
services to pregnant women with problematic substance use and newly parenting mothers and 
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their substance-exposed newborns, opening the Fir Square Combined Care Unit. Fir Square has 
12 individual patient rooms for integrated antepartum and postpartum care and four nursery beds 
if specialized treatment for newborns is needed. 
“Recovery is not this place of ultimate success, but 
involves human dignity and a growing conﬁdence in 
one’s self as choices and decisions are made. Fir can 
be that ﬁrst tiny light in the tunnel or it can be a very 
profound experience of change.”
—Fir Square staff nurse (Payne, 2007)
Pregnant women are often initiated into methadone treatment at Fir Square or Sheway, 
where the physicians and obstetricians/gynecologists are licensed to prescribe methadone main-
tenance treatment. In Canada, methadone maintenance treatment is available to pregnant women 
wherever there is a licensed methadone physician, but many methadone-prescribing physicians do 
not practice obstetrics, so, in practice, getting a prescription as a pregnant woman can be difﬁcult 
(Payne 2009).23 Fir Square and Sheway help ﬁll this gap.
Other programs in the country separate substance-exposed newborns from their mothers at 
birth, deprive them of sensory stimuli, and keep them in a nursery for their entire hospital stay; 
however, there is no evidence that this practice improves neonatal withdrawal.24 Since Fir Square 
has been able to accommodate mothers and babies staying in the same room, a prospective study 
reported a 40 percent decrease in the number of newborns requiring pharmacological treatment 
for withdrawal symptoms.25 Mothers can breastfeed at any maternal dose of methadone26 and Fir 
Square staff have observed that the more the babies are held, touched, and breastfed, the less likely 
they are to need morphine.27 
Any woman who is at least 15 weeks pregnant and dealing with substance use issues is eli-
gible for and welcomed to Fir Square. Doctors, street nurses, counselors, and friends refer women 
to the program; women can also self-refer. Lack of identiﬁcation or a ﬁxed address are not barriers 
to care. Women are admitted on a ﬁrst-come, ﬁrst-served basis, and while most of the clients are 
residents of Vancouver, the program will admit non-Vancouver residents. 
Fir Square maintains what the staff refer to as a “woman-centered” and harm reduction 
approach; allowing women back if they choose to leave against medical advice. 
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Vancouver Native Health Society
Vancouver Native Health Society is one of the funding partners of Sheway and is located just 
steps away in the Downtown Eastside. Vancouver Native Health Society delivers medical, social, 
and counseling services with a focus on reducing health disparities in the Aboriginal community 
of the Downtown Eastside.
The Aboriginal population is disproportionately affected by HIV/AIDS in Canada; in 2006, 
the percent of new HIV infections caused by injecting drug use among Aboriginal Canadians was 
53 percent, compared to 14 percent among non-Aboriginals.28
“Expecting a woman to stop using drugs and alcohol 
when she is not ready is not realistic and can be 
harmful, as these expectations will often result 
in her leaving the ward or not telling us she has 
used substances…” 
—Senior Practice Leader (Payne 2007)
The Vancouver Native Health Society provides services to native (and some non-native) 
individuals through its drop-in medical clinic. The clinic is open late into the evening and on 
weekends. All services provided on-site are free, including primary care, HIV/AIDS treatment and 
counseling, testing for sexually transmitted infections, methadone maintenance, and alcohol and 
drug counseling. The adjacent Eastside Pharmacy helps ensure that patients can easily access and 
adhere to treatment, and that pharmacists can communicate directly with physicians. No appoint-
ment is necessary, though waiting times can be long due to high demand.
Photo courtesy of Vancouver Native Health Society.
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In addition to the medical clinic, the Vancouver Native Health Society operates the Positive 
Outlook Program, providing support, care, and treatment services for people living with HIV 
and liaising between hospitals, community-based, and specialized services in the Downtown 
Eastside. 
The Positive Outlook Program includes nursing, social work, addiction counseling and out-
reach services, legal advocacy, food bank and meals, crisis intervention, and “maximally assisted 
medication therapy.” The medication therapy is an intensive case management model for people 
living with HIV and includes holding HIV medications for patients at the center and dispensing 
to patients only at the center. Program staff provide coverage seven days a week and see approxi-
mately 200 patients each day.29 Staff visit patients at their homes and deliver methadone or other 
medications when patients are unable to access the pharmacy. The Positive Outlook Program 
services are grounded in a fundamental respect for First Nations cultures and a commitment to 
client-centered, holistic service delivery.
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Public Health Program
The Open Society Institute’s Public Health Program aims to build societies committed to inclusion, 
human rights, and justice, in which health-related laws, policies, and practices are evidence-based 
and reﬂect these values. The program works to advance the health and human rights of marginalized 
people by building the capacity of civil society leaders and organizations, and by advocating for 
greater accountability and transparency in health policy and practice. The Public Health Program 
engages in ﬁve core strategies to advance its mission and goals: grantmaking, capacity building, 
advocacy, strategic convening, and mobilizing and leveraging funding. The Public Health Program 
works in Central and Eastern Europe, Southern and Eastern Africa, Southeast Asia, and China.
International Harm Reduction Development Program
The International Harm Reduction Development Program (IHRD), part of the Open Society 
Institute’s Public Health Program, works to advance the health and human rights of people who 
use drugs. Through grantmaking, capacity building, and advocacy, IHRD works to reduce HIV, fatal 
overdose and other drug-related harms; to decrease abuse by police and in places of detention; 
and to improve the quality of health services. IHRD supports community monitoring and advocacy, 
legal empowerment, and strategic litigation. Our work is based on the understanding that people 
unwilling or unable to abstain from illicit drug use can make positive changes to protect their health 
and that of their families and communities. 

The International Harm Reduction Development Program 
(IHRD), part of the Open Society Institute’s Public 
Health Program, works to advance the health and human 
rights of people who use drugs. Through grantmaking, 
capacity building, and advocacy, IHRD seeks to reduce 
HIV and other drug-related harms and to end policies and 
practices that marginalize and discriminate against drug 
users. We work to decrease abuse by law enforcement 
and to improve the quality of health services, through 
support of community monitoring and advocacy, legal 
empowerment, and strategic litigation. Our work is based 
on the understanding that people unwilling or unable to 
abstain from illicit drug use can make positive changes 
to protect their health and that of their families and 
communities.
